This inventor holds 1 USPTO granted patent. Top assignee: Meiji Seika Kaisha, Ltd.. Active years: 1990.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1990
Title: Kaysuyoshi Iwamatsu: Innovator in Antibacterial Agents
Introduction
Kaysuyoshi Iwamatsu is a notable inventor based in Yokohama, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antibacterial agents. His work has implications for treating various bacterial infections, showcasing the importance of innovation in healthcare.
Latest Patents
Iwamatsu holds a patent for cephalosporin compounds and antibacterial agents. This invention provides cephalosporin compounds represented by a specific general formula, wherein R¹ and R² can be hydrogen or a lower alkyl group of 1 to 5 carbon atoms. R³ is a lower alkyl group that may be substituted with halogen atoms, an alkenyl group, or a cycloalkylmethyl group of 3 to 6 carbon atoms. A can be a hydrogen atom or a residue of a nucleophilic compound, along with pharmacologically acceptable salts. These compounds exhibit broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa, and are effective against various β-lactamase-producing strains.
Career Highlights
Iwamatsu is associated with Meiji Seika Kaisha, Ltd., a company known for its commitment to pharmaceutical innovation. His work has contributed to advancements in antibacterial treatments, reflecting his dedication to improving public health through scientific research.
Collaborations
Iwamatsu has collaborated with notable colleagues such as Kenji Sakagami and Takashi Yoshida. These partnerships have likely enhanced the research and development process, leading to more effective solutions in the pharmaceutical industry.
Conclusion
Kaysuyoshi Iwamatsu's contributions to the field of antibacterial agents highlight the critical role of innovation in medicine. His patent for cephalosporin compounds demonstrates the potential for new treatments against resistant bacterial strains. The impact of his work continues to resonate in the healthcare sector, emphasizing the importance of ongoing research and development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
